Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.

Simon JA, Recknor C, Moffett AH Jr, Adachi JD, Franek E, Lewiecki EM, McClung MR, Mautalen CA, Ragi-Eis S, Nicholson GC, Muschitz C, Nuti R, Törring O, Wang A, Libanati C.

Menopause. 2013 Feb;20(2):130-7. doi: 10.1097/gme.0b013e318267f909.

PMID:
23010883
2.

Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population.

Pinto Neto LF, Ragi-Eis S, Vieira NF, Soprani M, Neves MB, Ribeiro-Rodrigues R, Miranda AE.

J Clin Densitom. 2011 Oct-Dec;14(4):434-9. doi: 10.1016/j.jocd.2011.06.004.

PMID:
22051092
3.

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.

Miller PD, Ragi-Eis S, Mautalen C, Ramirez F, Jonkanski I.

Bone. 2011 Dec;49(6):1317-22. doi: 10.1016/j.bone.2011.09.035. Epub 2011 Sep 16.

PMID:
21945737
4.

Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, Chionh SB, Chen Z, Curtis JR, Danielson ME, Hanley DA, Kroger H, Kung AW, Lesnyak O, Nieves J, Pluskiewicz W, El Rassi R, Silverman S, Schott AM, Rizzoli R, Luckey M; FRAX(®) Position Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):240-62. doi: 10.1016/j.jocd.2011.05.015.

PMID:
21810532
5.

FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

Cauley JA, El-Hajj Fuleihan G, Luckey MM; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):237-9. doi: 10.1016/j.jocd.2011.05.016.

PMID:
21810531
6.

Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA, Moayyeri A, Adler RA, Hans DB, Kendler DL, Diez-Perez A, Krieg MA, Masri BK, Lorenc RR, Bauer DC, Blake GM, Josse RG, Clark P, Khan AA; FRAX® Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):226-36. doi: 10.1016/j.jocd.2011.05.017.

PMID:
21810530
7.

FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):223-5. doi: 10.1016/j.jocd.2011.05.018.

PMID:
21810529
8.

Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

McCloskey EV, Vasikaran S, Cooper C; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):220-2. doi: 10.1016/j.jocd.2011.05.008.

PMID:
21810528
9.
10.
11.
12.

Official Positions for FRAX® clinical regarding smoking from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Dimai HP, Chandran M; FRAX(®)Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):190-3. doi: 10.1016/j.jocd.2011.05.011.

PMID:
21810524
13.
14.

FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

McCloskey EV, Binkley N; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):181-3. doi: 10.1016/j.jocd.2011.05.013.

PMID:
21810522
15.

Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.

Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey MM, McCloskey EV, Papapoulos SE, Poiana C, Rizzoli R; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):171-80. doi: 10.1016/j.jocd.2011.05.007.

PMID:
21810521
16.

Interpretation and use of FRAX in clinical practice.

Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV; Task Force of the FRAX Initiative.

Osteoporos Int. 2011 Sep;22(9):2395-411. doi: 10.1007/s00198-011-1713-z. Epub 2011 Jul 21. Review.

PMID:
21779818
17.

Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.

Silverman S, Viswanathan HN, Yang YC, Wang A, Boonen S, Ragi-Eis S, Fardellone P, Gilchrist N, Lips P, Nevitt M, Palacios Gil-Antuñano S, Pavelka K, Revicki D, Simon J, Macarios D, Siris ES.

Osteoporos Int. 2012 Apr;23(4):1361-9. doi: 10.1007/s00198-011-1720-0. Epub 2011 Jul 19.

PMID:
21769664
18.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
19.

The effects of tibolone in older postmenopausal women.

Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators.

N Engl J Med. 2008 Aug 14;359(7):697-708. doi: 10.1056/NEJMoa0800743.

20.

Is it ethical to use placebos in osteoporosis trials?

Ragi-Eis S, Zerbini CA, Provenza JR, Griz LH, de Gregório LH, Russo LA, Silva NA, Borges JL, de Souza AC, Castro ML, Lewiecki EM.

J Clin Densitom. 2006 Jul-Sep;9(3):274-80.

PMID:
16931344
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk